ストックスクリーナーアプリを入手
91.32
3.70%
-3.51
アフターアワーズ：
91.41
0.09
+0.10%
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings and a Promising 14.42% Upside Potential - DirectorsTalk Interviews
TD Asset Management Inc Acquires 34,096 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating - marketscreener.com
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - lelezard.com
Takeda Pharmaceutical and Protagonist Therapeutics Inc (NASDAQ: PTGX) jointly announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their co-developed drug Rusfertide and granted it prior - Bitget
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Vanguard Group Inc. - MarketBeat
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance
Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative - Sahm
PTGX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - Sahm
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines - TipRanks
Understanding the Setup: (PTGX) and Scalable Risk - Stock Traders Daily
Protagonist Therapeutics (PTGX) Gets Price Target Lift from TD C - GuruFocus
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00 - MarketBeat
PTGX: Today's Analyst Ratings and Price Target Updates | PTGX St - GuruFocus
Protagonist Therapeutics (PTGX) Sees Analyst Rating Update from Barclays | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 - MarketBeat
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - AOL.com
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Desert Sun
Citizens raises Protagonist Therapeutics stock price target on drug approvals - Investing.com UK
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Register-Guard
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Protagonist Therapeutics: Fourth Quarter Earnings Overview - Bitget
Protagonist Therapeutics: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - FinanzNachrichten.de
Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Protagonist Therapeutics Q4 revenue drops on lower milestone payments - TradingView
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q4 Revenue $7.4M - marketscreener.com
[8-K] Protagonist Therapeutics, Inc Reports Material Event | PTGX SEC FilingForm 8-K - Stock Titan
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - The Motley Fool
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance - AOL.com
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Promising Biotech with 17.7% Upside Potential - DirectorsTalk Interviews
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - ACCESS Newswire
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
RTW INVESTMENTS, LP Reduces Stake in Protagonist Therapeutics Inc - GuruFocus
Can Protagonist Therapeutics Inc. sustain its profitabilityWeekly Trade Summary & AI Driven Stock Movement Reports - mfd.ru
Protagonist Therapeutics showcases pioneering peptide technology - Traders Union
Lewis Williams Sells 18,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - Defense World
Polycythemia Vera Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):